ProQR bags €7.7M to advance RNA Therapy for Rett Syndrome
Leiden-based ProQR Therapeutics, a biotech company specializing in RNA therapies, has secured €7.7 million ($8.1 million USD) in additional funding from the Rett Syndrome Research Trust (RSRT).

The best Articles in our Network

Previous
Next